AMPKγ1 / Longevity (Liver) Program

About Korro Bio

Korro Bio is developing transformative genetic medicines by co-opting the body's natural RNA editing machinery to correct disease-causing mutations or modulate protein function. The company's OPERA® platform and first-generation CHORD™ oligonucleotides are designed for high specificity, transient activity, and delivery via clinically validated methods like GalNAc. With a pipeline focused on liver and CNS diseases, Korro is advancing multiple wholly-owned programs, recently securing an $85 million private placement to fund its development efforts.

Therapeutic Areas